Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,590
  • Shares Outstanding, K 62,176
  • Annual Sales, $ 115,530 K
  • Annual Income, $ -30,600 K
  • 60-Month Beta 1.58
  • Price/Sales 0.82
  • Price/Cash Flow N/A
  • Price/Book 1.41
Trade DTIL with:

Options Overview Details

View History
  • Implied Volatility 176.58% ( -33.19%)
  • Historical Volatility 87.62%
  • IV Percentile 82%
  • IV Rank 24.45%
  • IV High 537.59% on 06/17/22
  • IV Low 59.76% on 11/10/21
  • Put/Call Vol Ratio 0.03
  • Today's Volume 332
  • Volume Avg (30-Day) 232
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 7,941
  • Open Int (30-Day) 7,385

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.40
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.50
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -110.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4100 +17.02%
on 08/02/22
1.7700 -6.78%
on 08/08/22
-0.0900 (-5.17%)
since 07/08/22
3-Month
1.1100 +48.65%
on 06/16/22
2.2100 -25.34%
on 06/08/22
-0.2100 (-11.29%)
since 05/10/22
52-Week
1.1100 +48.65%
on 06/16/22
14.3800 -88.53%
on 09/01/21
-8.6600 (-84.00%)
since 08/10/21

Most Recent Stories

More News
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases....

REGN : 641.49 (+3.11%)
BAYRY : 13.3500 (+0.71%)
KOD : 12.50 (+14.47%)
DTIL : 1.6500 (+7.84%)
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.

JAZZ : 157.43 (+0.56%)
TECH : 379.95 (+5.21%)
AXSM : 48.36 (+8.04%)
DTIL : 1.6500 (+7.84%)
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates

Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.

TECH : 379.95 (+5.21%)
ACAD : 16.15 (-0.43%)
ATRA : 4.95 (+5.54%)
DTIL : 1.6500 (+7.84%)
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings

Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

PFE : 49.95 (+0.34%)
TECH : 379.95 (+5.21%)
GBT : 66.84 (+0.38%)
DTIL : 1.6500 (+7.84%)
Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DTIL : 1.6500 (+7.84%)
ARCT : 17.48 (-4.11%)
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results...

DTIL : 1.6500 (+7.84%)
Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues

Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.

BEAM : 65.73 (+7.82%)
ATRA : 4.95 (+5.54%)
DCPH : 17.20 (+1.53%)
DTIL : 1.6500 (+7.84%)
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.

REGN : 641.49 (+3.11%)
JNJ : 170.67 (+0.29%)
BAYRY : 13.3500 (+0.71%)
DTIL : 1.6500 (+7.84%)
Editas' (EDIT) Loss Narrows in Q2, Revenues Trump Estimates

Editas (EDIT) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates. Focus remains on the lead candidate, EDIT-101.

BEAM : 65.73 (+7.82%)
ATRA : 4.95 (+5.54%)
EDIT : 18.55 (+3.11%)
DTIL : 1.6500 (+7.84%)
Novo Nordisk's (NVO) Q2 Earnings Miss, Sales Beat Estimates

Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

NVO : 107.51 (+2.78%)
BEAM : 65.73 (+7.82%)
ATRA : 4.95 (+5.54%)
DTIL : 1.6500 (+7.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.

See More

Key Turning Points

3rd Resistance Point 1.8400
2nd Resistance Point 1.7500
1st Resistance Point 1.7000
Last Price 1.6500
1st Support Level 1.5600
2nd Support Level 1.4700
3rd Support Level 1.4200

See More

52-Week High 14.3800
Fibonacci 61.8% 9.3109
Fibonacci 50% 7.7450
Fibonacci 38.2% 6.1791
Last Price 1.6500
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar